HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chewing Gum Acceptable Menthol Delivery Form, Petitioners Suggest

This article was originally published in The Tan Sheet

Executive Summary

A chewing gum dosage vehicle could deliver 5 mg of menthol in a 20-minute period, similar to already-approved lozenges, according to a citizen petition filed with FDA May 25.

You may also be interested in...



OTC Antitussive Menthol Chewing Gum Requires NDA Deviation – FDA

A menthol-containing topical antitussive drug with chewing gum as a delivery form necessitates submission of an NDA deviation, FDA states

Wrigley

Healthcare division has signed a $25 mil. agreement to acquire complete assets of Gum Tech's gum business, firm announces March 15. Under the deal, Wrigley will obtain rights to Gum Tech's manufacturing facility and plant as well as existing manufacturing contracts. Gum Tech will retain its interest in Gel Tech and its joint venture with Swedish Match. Wrigley said the acquisition will enable its new healthcare division to more quickly and cost effectively develop innovative products than it would have by building its own facility. Wrigley Healthcare began shipping Surpass antacid chewing gum, its first OTC product, Feb. 19 (1"The Tan Sheet" Feb. 19, p. 8)

Wrigley Healthcare's Surpass Antacid Gum Shipping Feb. 19

Newly created Wrigley Healthcare is supporting the launch of its Surpass antacid chewing gum with a $40 mil. marketing and advertising campaign.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel